Lead Product(s) : Bifidobacterium Bifidum
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Undisclosed
Sponsor : LALLEMAND HEALTH SOLUTIONS
Deal Size : Inapplicable
Deal Type : Inapplicable
Resilience to Antibiotic-Induced Obesogenic Microbiota by Microbiota Modulation Mechanism
Details : Bifidobacterium Bifidum is a Microorganism drug candidate, which is currently being evaluated in clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
May 16, 2025
Lead Product(s) : Bifidobacterium Bifidum
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Sponsor : LALLEMAND HEALTH SOLUTIONS
Deal Size : Inapplicable
Deal Type : Inapplicable